Incadronic acid (BioDeep_00000179992)

   

human metabolite blood metabolite


代谢物信息卡片


Hydronium (cycloheptylammonio)methylene-1,1-bisphosphonate

化学式: C8H19NO6P2 (287.0687574)
中文名称: 英卡膦酸
谱图信息: 最多检出来源 Homo sapiens(blood) 12.5%

分子结构信息

SMILES: C1CCCC(CC1)NC(P(=O)(O)O)P(=O)(O)O
InChI: InChI=1S/C8H19NO6P2/c10-16(11,12)8(17(13,14)15)9-7-5-3-1-2-4-6-7/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15)

描述信息

C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor
D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates

同义名列表

8 个代谢物同义名

Hydronium (cycloheptylammonio)methylene-1,1-bisphosphonate; [(cycloheptylamino)(phosphono)methyl]phosphonic acid; Cycloheptylaminomethylene-1,1-bisphosphonate; Hydronium incadronate; Incadronic acid; Cimadronate; incadronate; Incadronic



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Toshiki Kijima, Yasuhisa Fujii, Taisuke Suyama, Yuhei Okubo, Junji Yonese, Iwao Fukui. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. International journal of urology : official journal of the Japanese Urological Association. 2008 Jun; 15(6):546-7. doi: 10.1111/j.1442-2042.2008.02044.x. [PMID: 18489646]
  • Sung-Bae Kim, Jung Shin Lee, Heung Tae Kim, Yong Hyuck Im, Tae Won Kim, Baek Yeol Ryoo, Yeon Hee Park, Joon Oh Park, Keunchil Park, Hitoshi Katoh, Minoru Yamamoto. Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. Current therapeutic research, clinical and experimental. 2007 May; 68(3):193-204. doi: 10.1016/j.curtheres.2007.06.004. [PMID: 24683210]
  • Yutaka Suzuki, Shinji Fukushima, Takaya Iwai, Yoshio Ishibashi, Nobuo Omura, Nobuyoshi Hanyu, Hideyuki Kashiwagi, Katsuhiko Yanaga, Mitsuyoshi Urashima. Bisphosphonate incadronate prevents total gastrectomy-induced osteopenia in rats. Bone. 2004 Dec; 35(6):1346-52. doi: 10.1016/j.bone.2004.09.006. [PMID: 15589215]
  • Hiroya Senzaki, Takahiro Yasui, Atsushi Okada, Yasunori Ito, Keiichi Tozawa, Kenjiro Kohri. Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model. Urological research. 2004 Jun; 32(3):223-8. doi: 10.1007/s00240-004-0409-7. [PMID: 15064876]
  • Ying-ying Hu, Wei-bo Xia, Huai-cheng Liu, Xun-wu Meng, Xue-ying Zhou, Xiao-ping Xing. [Changes of urinary deoxypyridinoline crosslink/creatinine in rats after ovariectomy and anti-osteoporotic intervention]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae. 2003 Jun; 25(3):271-4. doi: . [PMID: 12905738]
  • Haruhiko Tokuda, Atsushi Harada, Kouseki Hirade, Hiroyuki Matsuno, Hidenori Ito, Kanefusa Kato, Yutaka Oiso, Osamu Kozawa. Incadronate amplifies prostaglandin F2 alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Enhancement of MAPK activity. The Journal of biological chemistry. 2003 May; 278(21):18930-7. doi: 10.1074/jbc.m209159200. [PMID: 12646577]
  • Kyoko Teramura, Shinji Fukushima, Takaya Iwai, Kazutoshi Nozaki, Satoshi Kokubo, Koichiro Takahashi. Incadronate inhibits osteoporosis in ovariectomized rats. European journal of pharmacology. 2002 Dec; 457(1):51-6. doi: 10.1016/s0014-2999(02)02659-6. [PMID: 12460643]
  • Leo Widler, Knut A Jaeggi, Markus Glatt, Klaus Müller, Rolf Bachmann, Michael Bisping, Anne-Ruth Born, Reto Cortesi, Gabriela Guiglia, Heidi Jeker, Rémy Klein, Ueli Ramseier, Johann Schmid, Gerard Schreiber, Yves Seltenmeyer, Jonathan R Green. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). Journal of medicinal chemistry. 2002 Aug; 45(17):3721-38. doi: 10.1021/jm020819i. [PMID: 12166945]
  • Kyoko Teramura, Shinji Fukushima, Kazutoshi Nozaki, Satoshi Kokubo, Koichiro Takahashi. Comparison of incadronate and alfacalcidol on increased bone turnover caused by ovariectomy in rats. European journal of pharmacology. 2002 Aug; 449(1-2):191-6. doi: 10.1016/s0014-2999(02)01979-9. [PMID: 12163124]
  • T Matsumoto, N Nagata, N Horikoshi, I Adachi, Y Ohashi, E Ogata. Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia. The Journal of international medical research. 2002 May; 30(3):230-43. doi: 10.1177/147323000203000303. [PMID: 12166339]
  • Makoto Shigematsu, Susumu Shomi, Hiroshi Iwao, Hironobu Ochi. New bone-seeking agent: animal study of Tc-99m-incadronate. Annals of nuclear medicine. 2002 Feb; 16(1):55-9. doi: 10.1007/bf02995292. [PMID: 11922209]
  • Y Ohno, Y Yamada, T Usu, K Takahashi, F Tsuchiya, H Ohtani, H Sato, Y Sawada, T Iga. Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats. Biological & pharmaceutical bulletin. 2001 Nov; 24(11):1290-3. doi: 10.1248/bpb.24.1290. [PMID: 11725966]
  • Y Tamura, N Miyakoshi, E Itoi, T Abe, T Kudo, T Tsuchida, Y Kasukawa, K Sato. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2001 Mar; 16(3):541-9. doi: 10.1359/jbmr.2001.16.3.541. [PMID: 11277272]
  • K Yamaguchi, K Motegi, Y Iwakura, Y Endo. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. British journal of pharmacology. 2000 Aug; 130(7):1646-54. doi: 10.1038/sj.bjp.0703460. [PMID: 10928970]
  • S Oura, T Sakurai, G Yoshimura, T Tamaki, T Umemura, Y Kokawa, Y Naito. [Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 1999 Oct; 26(11):1623-8. doi: NULL. [PMID: 10553421]
  • M Ito, M Chokki, Y Ogino, Y Satomi, Y Azuma, T Ohta, M Kiyoki. Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo. Calcified tissue international. 1998 Aug; 63(2):143-7. doi: 10.1007/s002239900505. [PMID: 9685520]
  • K Takahashi, A Shirahata, S Fukushima, S Kokubo, K Teramura, S Usuda. Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats. Japanese journal of pharmacology. 1998 Feb; 76(2):155-63. doi: 10.1254/jjp.76.155. [PMID: 9541278]
  • T Usui, Y Oiso, A Tomita, E Ogata, T Uchida, K Ikeda, T Watanabe, S Higuchi. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia. International journal of clinical pharmacology and therapeutics. 1997 Jun; 35(6):239-44. doi: NULL. [PMID: 9208339]
  • T Usui, S Tanaka, T Sonoda, Y Ozawa, K Teramura, E Nakamura, T Watanabe, S Higuchi. Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases. Xenobiotica; the fate of foreign compounds in biological systems. 1997 May; 27(5):479-87. doi: 10.1080/004982597240442. [PMID: 9179988]
  • T Usui, T Watanabe, S Higuchi. Effect of dose, sex and age on the drug disposition of incadronate, a new bisphosphonate, in rat bone. Pharmacology & toxicology. 1996 Nov; 79(5):254-8. doi: 10.1111/j.1600-0773.1996.tb00269.x. [PMID: 8936559]
  • P David, H Nguyen, A Barbier, R Baron. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1996 Oct; 11(10):1498-507. doi: 10.1002/jbmr.5650111017. [PMID: 8889850]
  • H Motoie, H Kanoh, S Ogata, K Kawamuki, H Shikama, T Fujikura. Prevention of bone loss by bisphosphonate YM175 in ovariectomized dogs with dietary calcium restriction. Japanese journal of pharmacology. 1996 Jul; 71(3):239-46. doi: 10.1254/jjp.71.239. [PMID: 8854206]
  • T Usui, T Watanabe, S Higuchi. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug metabolism and disposition: the biological fate of chemicals. 1995 Nov; 23(11):1214-9. doi: NULL. [PMID: 8591721]
  • M Gen. [Effects of bisphosphonates on vitamin A-induced bone resorption in thyroparathyroidectomized rat]. Nihon Seikeigeka Gakkai zasshi. 1995 Nov; 69(11):1193-207. doi: NULL. [PMID: 8568374]
  • A Okazaki, H Sakai, T Matsuzawa, C J Perkin, P W East. Intravenous single and repeated dose toxicity studies of cimadronate (YM175), a novel bisphosphonate, in rats. The Journal of toxicological sciences. 1995 Oct; 20 Suppl 1(?):15-26. doi: 10.2131/jts.20.supplementi_15. [PMID: 7490786]
  • A Okazaki, T Matsuzawa, C J Perkin, M H Barker. Intravenous single and repeated dose toxicity studies of cimadronate (YM175), a novel bisphosphonate, in beagle dogs. The Journal of toxicological sciences. 1995 Oct; 20 Suppl 1(?):27-36. doi: 10.2131/jts.20.supplementi_27. [PMID: 7490787]
  • S Fukumoto, T Matsumoto, K Takebe, T Onaya, S Eto, H Nawata, E Ogata. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. The Journal of clinical endocrinology and metabolism. 1994 Jul; 79(1):165-70. doi: 10.1210/jcem.79.1.8027221. [PMID: 8027221]
  • T Usui, T Watanabe, S Higuchi. Determination of a new bisphosphonate, YM175, in plasma, urine and bone by high-performance liquid chromatography with electrochemical detection. Journal of chromatography. 1992 Dec; 584(2):213-20. doi: 10.1016/0378-4347(92)80578-e. [PMID: 1484106]
  • Y Nagao, Y Ishitobi, H Kinoshita, S Fukushima, H Kawashima. YM175, a new bisphosphonate, increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity. Biochemical and biophysical research communications. 1991 Nov; 180(3):1172-8. doi: 10.1016/s0006-291x(05)81319-1. [PMID: 1953769]
  • H Kawashima, Y Nagao, Y Ishitobi, H Kinoshita, S Fukushima. Bisphosphonates increase serum 1,25-dihydroxyvitamin D in rats via stimulating renal production of the hormone. Contributions to nephrology. 1991; 91(?):140-5. doi: 10.1159/000420170. [PMID: 1800007]